Literature DB >> 8884537

Effect of glycemic control on growth hormone and IGFBP-1 secretion in patients with type I diabetes mellitus.

L R Salgado1, M Semer, M Nery, M Knoepfelmacher, A C Lerário, G Póvoa, S Jana, S M Villares, B L Wajchenberg, B Liberman, W Nicolau.   

Abstract

Growth hormone (GH) secretion disorders have been reported in poorly controlled type I diabetes mellitus patients. Our work was aimed to evaluate GH secretion in 9 type I young diabetes mellitus patients as well as the low molecular weight IGF-binding protein secretion (IGFBP-1) in 5 of them. The patients did not show any signs of malnutrition or neurovascular complications, neither were they on any medication except for insulin. The study protocol included blood samples collection during a 24-h period for measurement of glucose, glycated hemoglobin, GH IGF-I and IGFBP-1 levels under two situations: on poor glycemic control and after 2-3 months on better control through systematic diet, low in carbohydrates and increase in insulin dosage. GH secretion data were analyzed by Cluster algorithm for pulsatility parameters; for rhythm assessment Cosinor method was used. The first study (poor control) reported significant increase of GH maximal and incremental amplitude and duration pulse values, when compared to the second study (better control). Mean 24-h secretion values as well mean GH for interpulse intervals (valleys) decreased, although not statistically significant. The fraction of pulsatile GH/24 h GH did not change significantly with better glycemic control. No changes in pulse frequency were observed. Mean IGF-I concentrations were significantly higher when patients were on better glycemic control. An ultradian variation for GH secretion was noticed in the first study (poor control) and a circadian variation in the second one (better control). IGFBP-1 analysis showed significant decrease of the mean 24-h values under better glycemic control. Linear regression analysis demonstrated a correlation between IGFBP-1 levels and fasting glucose levels. A circadian variation was present in IGFBP-1 secretion, irrespective of glycemic control. Therefore, we concluded that for type I diabetic patients: 1. GH secretion is increased on poor control, through maximal, incremental amplitude and pulse duration values; 2. IGFBP-1 values were significantly reduced and IGF-1 levels significantly higher after better glycemic control; 4. GH ultradian secretion is reported on poor control, and circadian on the better one, 5. IGFBP-1 circadian secretion occurred irrespective of glycemic control.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8884537     DOI: 10.1007/BF03349888

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  27 in total

1.  Cluster analysis: a simple, versatile, and robust algorithm for endocrine pulse detection.

Authors:  J D Veldhuis; M L Johnson
Journal:  Am J Physiol       Date:  1986-04

2.  Insulin regulates the serum levels of low molecular weight insulin-like growth factor-binding protein.

Authors:  A M Suikkari; V A Koivisto; E M Rutanen; H Yki-Järvinen; S L Karonen; M Seppälä
Journal:  J Clin Endocrinol Metab       Date:  1988-02       Impact factor: 5.958

3.  Diurnal rhythm of growth hormone-independent binding protein for insulin-like growth factors in human plasma.

Authors:  R C Baxter; C T Cowell
Journal:  J Clin Endocrinol Metab       Date:  1987-09       Impact factor: 5.958

4.  Serum levels of the low molecular weight form of insulin-like growth factor binding protein in healthy subjects and patients with growth hormone deficiency, acromegaly and anorexia nervosa.

Authors:  K Hall; G Lundin; G Póvoa
Journal:  Acta Endocrinol (Copenh)       Date:  1988-07

5.  Insulin regulates the 35 kDa IGF binding protein in patients with diabetes mellitus.

Authors:  K Brismar; M Gutniak; G Povoa; S Werner; K Hall
Journal:  J Endocrinol Invest       Date:  1988-09       Impact factor: 4.256

6.  Serum growth hormone patterns in juvenile diabetes.

Authors:  A P Hansen
Journal:  Dan Med Bull       Date:  1972-04

7.  Serum levels of insulin-like growth factor (IGF) I, II and IGF binding protein in diabetic adolescents treated with continuous subcutaneous insulin infusion.

Authors:  K Hall; B L Johansson; G Póvoa; B Thalme
Journal:  J Intern Med       Date:  1989-04       Impact factor: 8.989

8.  Pituitary response to growth hormone-releasing factor in diabetes. Failure of glucose-mediated suppression.

Authors:  M Press; W V Tamborlane; M O Thorner; W Vale; J Rivier; J M Gertner; R S Sherwin
Journal:  Diabetes       Date:  1984-08       Impact factor: 9.461

9.  Somatotropin pulse frequency and basal concentrations are increased in acromegaly and are reduced by successful therapy.

Authors:  M L Hartman; J D Veldhuis; M L Vance; A C Faria; R W Furlanetto; M O Thorner
Journal:  J Clin Endocrinol Metab       Date:  1990-05       Impact factor: 5.958

10.  Alterations in the pulsatile mode of growth hormone release in men and women with insulin-dependent diabetes mellitus.

Authors:  C M Asplin; A C Faria; E C Carlsen; V A Vaccaro; R E Barr; A Iranmanesh; M M Lee; J D Veldhuis; W S Evans
Journal:  J Clin Endocrinol Metab       Date:  1989-08       Impact factor: 5.958

View more
  6 in total

Review 1.  The endocrine system in diabetes mellitus.

Authors:  Hisham Alrefai; Hisham Allababidi; Shiri Levy; Joseph Levy
Journal:  Endocrine       Date:  2002-07       Impact factor: 3.633

Review 2.  Medical management of functioning pituitary adenoma: an update.

Authors:  Yutaka Oki
Journal:  Neurol Med Chir (Tokyo)       Date:  2014-11-29       Impact factor: 1.742

Review 3.  Regulation of IGFBP-1 in Metabolic Diseases.

Authors:  Jae-Hoon Bae; Dae-Kyu Song; Seung-Soon Im
Journal:  J Lifestyle Med       Date:  2013-09-30

Review 4.  Novel Actions of Growth Hormone in Podocytes: Implications for Diabetic Nephropathy.

Authors:  Dhanunjay Mukhi; Rajkishor Nishad; Ram K Menon; Anil Kumar Pasupulati
Journal:  Front Med (Lausanne)       Date:  2017-07-12

Review 5.  Early Worsening of Retinopathy in Type 1 and Type 2 Diabetes After Rapid Improvement in Glycaemic Control: A Systematic Review.

Authors:  Uazman Alam; Philip Burgess; Handan Akil; Jamie Burgess; Sarah Nevitt; Simon P Harding
Journal:  Diabetes Ther       Date:  2021-12-20       Impact factor: 2.945

6.  Renal effects of growth hormone in health and in kidney disease.

Authors:  Dieter Haffner; Andrea Grund; Maren Leifheit-Nestler
Journal:  Pediatr Nephrol       Date:  2021-06-18       Impact factor: 3.714

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.